IPSCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Century Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.47+0.10 (+7.30%)
Close on Oct 19, 2026
- Market cap
- $302.49M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.93 (+171.1%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Century Therapeutics, Inc. grew revenue 1556.8% to $109.16M over fiscal 2025. Free cash flow was -$88.09M.
Revenue
$109.16M
+1556.8% vs. a year earlier
Operating income
-$116.99M
TTM Q2 2026
Free cash flow
-$88.09M
TTM Q2 2026
EPS, diluted
-$0.90
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $302.49M
- P/E ratio
- –
- Price to sales
- 2.77
- Price to book
- 1.30
- Dividend yield
- –
- Free cash flow yield
- -29.12%
Fundamentals
- Revenue
- $109.16M
- Net income
- -$109.79M
- EPS, diluted
- -$0.90
- Free cash flow
- -$88.09M
- Book value per share
- $1.13
- Diluted shares
- 206M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$116.99M
Net income
-$109.79M
EPS, diluted
-$0.90
Free cash flow
-$88.09M
Reported periodTrailing twelve months